CR20230485A - Derivados de fósforo como nuevos inhibidores de sos1 - Google Patents

Derivados de fósforo como nuevos inhibidores de sos1

Info

Publication number
CR20230485A
CR20230485A CR20230485A CR20230485A CR20230485A CR 20230485 A CR20230485 A CR 20230485A CR 20230485 A CR20230485 A CR 20230485A CR 20230485 A CR20230485 A CR 20230485A CR 20230485 A CR20230485 A CR 20230485A
Authority
CR
Costa Rica
Prior art keywords
compounds
novel
phosphorus derivatives
sos1
sos1 inhibitors
Prior art date
Application number
CR20230485A
Other languages
English (en)
Inventor
Timo Stellfeld
Keith Graham
Jens SCHRÖDER
Michael Erkelenz
Steffen Gressies
Atanas Marinov Kamburov
Roman Hillig
Christoph Philipp Hethey
Jeremie Xavier G Mortier
Matthias Arlt
Benjamin Bader
Katrin Nowak-Reppel
Felix Pape
Gerhard Siemeister
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of CR20230485A publication Critical patent/CR20230485A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • C07F9/65685—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine oxide or thioxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención abarca los derivados de fósforo de la fórmula general (I): (I), en donde R<em>1</em>, R<em>2</em>, R<em>3</em>, R<em>4</em>, R<em>5</em>, R<em>6</em>, X<em>1</em>, X<em>2</em>, X<em>3</em>, X<em>4</em> e Y son como se definen en el presente documento, métodos de preparación de dichos compuestos, compuestos intermedios útiles para la preparación de dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden dichos compuestos y el uso de dichos compuestos para la fabricación de composiciones farmacéuticas para el tratamiento o profilaxis de enfermedades, en particular de trastornos hiperproliferativos, especialmente enfermedades asociadas a SOS1, como agente único o en combinación con otros ingredientes activos.
CR20230485A 2021-04-14 2022-04-13 Derivados de fósforo como nuevos inhibidores de sos1 CR20230485A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21168256.2A EP4074317A1 (en) 2021-04-14 2021-04-14 Phosphorus derivatives as novel sos1 inhibitors
PCT/EP2022/059857 WO2022219035A1 (en) 2021-04-14 2022-04-13 Phosphorus derivatives as novel sos1 inhibitors

Publications (1)

Publication Number Publication Date
CR20230485A true CR20230485A (es) 2023-12-12

Family

ID=75529812

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230485A CR20230485A (es) 2021-04-14 2022-04-13 Derivados de fósforo como nuevos inhibidores de sos1

Country Status (17)

Country Link
EP (2) EP4074317A1 (es)
JP (1) JP2024513595A (es)
KR (1) KR20230170032A (es)
CN (1) CN117500507A (es)
AR (1) AR125672A1 (es)
AU (1) AU2022258751A1 (es)
BR (1) BR112023019030A2 (es)
CA (1) CA3216503A1 (es)
CL (1) CL2023003045A1 (es)
CO (1) CO2023013469A2 (es)
CR (1) CR20230485A (es)
DO (1) DOP2023000218A (es)
EC (1) ECSP23077322A (es)
IL (1) IL307448A (es)
PE (1) PE20240022A1 (es)
TW (1) TW202304467A (es)
WO (1) WO2022219035A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3182745A1 (en) * 2020-05-09 2021-11-18 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Sos1 inhibitor containing phosphorus
CN116425796A (zh) * 2022-01-12 2023-07-14 如东凌达生物医药科技有限公司 一类嘧啶并杂环类化合物、制备方法和用途
WO2024056782A1 (en) * 2022-09-16 2024-03-21 Bayer Aktiengesellschaft Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2015A (en) 1841-03-26 Improvement in rotary steam-engines
GT198900008A (es) 1988-01-29 1990-07-17 Derivados de quinolina, quinazolina y cinolina.
IL89027A (en) 1988-01-29 1993-01-31 Lilly Co Eli Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5236925A (en) 1991-10-24 1993-08-17 American Home Products Corporation Fused pyrimidines as angiotensin II antagonists
JP2001514173A (ja) 1997-08-25 2001-09-11 バイエル・コーポレーシヨン Ｎｐｙｙ５アンタゴニストとしての複素環式ケトン
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2003299943A1 (en) * 2002-12-23 2004-07-22 Ariad Pharmaceuticals, Inc. Heterocycles and uses thereof
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
WO2005005382A2 (en) 2003-07-02 2005-01-20 Cytokinetics, Inc. Compounds, compositions and methods
ES2279446T3 (es) 2003-08-15 2007-08-16 MERCK &amp; CO., INC. Antagonistas nmda/nr2b de 4-cicloalquilaminopirazolo pirimidina.
AU2005238386A1 (en) 2004-04-30 2005-11-10 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof as an MMP-13 inhibitor
SE0401540D0 (sv) 2004-06-15 2004-06-15 Astrazeneca Ab New compounds
ITMI20042042A1 (it) 2004-10-26 2005-01-26 Pharmeste Srl Derivati solfonammidici antagonisti del recettore dei vanilloidi trpv1
EP2526942B1 (en) 2005-06-08 2017-08-09 The University of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
KR101083490B1 (ko) 2006-05-23 2011-11-16 에프. 호프만-라 로슈 아게 피리도피리미딘온 유도체
JP5550352B2 (ja) 2007-03-15 2014-07-16 ノバルティス アーゲー 有機化合物およびその使用
JP2008280341A (ja) 2007-04-12 2008-11-20 Sumitomo Chemical Co Ltd ヒドラジド化合物およびその防除用途
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
FR2929615B1 (fr) 2008-04-02 2010-12-17 Tfchem Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.
HUE035029T2 (en) 2008-05-21 2018-03-28 Ariad Pharma Inc Kinase inhibitor phosphorus derivatives
AR073354A1 (es) 2008-07-31 2010-11-03 Genentech Inc Compuestos de pirimidina, composiciones farmaceuticas y su uso en el tratamiento del cancer.
NZ591793A (en) 2008-08-27 2012-11-30 Takeda Pharmaceutical Substituted 1-(4-fluoro-5-(2-fluoropyridin-3-yl)-1-((pyrindin-2-yl)sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine compounds
SI2401267T1 (sl) 2009-02-27 2014-05-30 Ambit Biosciences Corporation Derivati kinazolina, ki modulirajo JAK-kinazo, in njihova uporaba v postopkih
US8461164B2 (en) 2009-08-31 2013-06-11 Dow Agrosciences, Llc. Pteridines and their use as agrochemicals
LT3575288T (lt) 2009-09-03 2021-12-10 Bristol-Myers Squibb Company Chinazolinai kaip kalio jonų kanalų inhibitoriai
WO2012030918A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
US20130225578A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
WO2012030948A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
BR112013005223A2 (pt) 2010-09-03 2016-05-03 Bayer Ip Gmbh "pirimidinonas e dihidropirimidinonas fusionadas substituídas."
MX367623B (es) 2010-10-20 2019-08-29 Gruenenthal Gmbh 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
WO2012066122A1 (en) 2010-11-18 2012-05-24 Syngenta Participations Ag 2 - (pyridin- 2 -yl) -quinazoline derivatives and their use as microbicides
UY33775A (es) 2010-12-10 2012-07-31 Gilead Sciences Inc Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
CN102584828B (zh) 2011-01-14 2016-01-27 上海艾力斯医药科技有限公司 吡咯烷[3，4-d]嘧啶衍生物、制备方法及其应用
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
CN102911172A (zh) 2011-08-04 2013-02-06 上海恒瑞医药有限公司 杂芳基并嘧啶类衍生物、其制备方法和用途
KR20140074912A (ko) 2011-09-01 2014-06-18 에프. 호프만-라 로슈 아게 피롤로피라진 키나아제 억제제
CN103387490B (zh) 2012-05-09 2015-08-26 中国科学院兰州化学物理研究所 一种甲苯羰化合成苯乙酸的方法
PT2861604T (pt) 2012-06-08 2017-05-05 Gilead Sciences Inc Inibidores macrocíclicos de vírus flaviridae
US9868707B2 (en) 2012-12-20 2018-01-16 Sanford-Burnham Medical Research Institute Small molecule agonists of neurotensin receptor 1
PE20151722A1 (es) 2013-01-08 2015-11-19 European Molecular Biology Lab Embl Derivados de pirimidona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral
CA2908315A1 (en) 2013-03-29 2014-10-02 Vida Therapeutics, Inc. Cosmetic uses and methods for indoline granzyme b inhibitor compositions
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
BR112016001954A2 (pt) 2013-07-31 2017-08-01 Gilead Sciences Inc composto, composição farmacêutica, e, método para tratar uma doença ou condição
WO2015155306A1 (en) 2014-04-11 2015-10-15 Almirall, S.A. New trpa1 antagonists
CN106715435B (zh) 2014-09-15 2019-10-01 卢郡控股(开曼)有限公司 作为nr2b nmda受体拮抗剂的吡咯并嘧啶衍生物
EP3453710B1 (en) 2014-09-17 2022-09-21 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2016049048A1 (en) 2014-09-22 2016-03-31 Rugen Holdings (Cayman) Limited Treatment of anxiety disorders and autism spectrum disorders
CN104803954B (zh) 2015-04-30 2018-01-26 上海应用技术学院 一种福沙那韦中间体的制备方法
EA037990B1 (ru) 2015-07-08 2021-06-21 Св6 Терапьютикс (Най) Лимитед Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин
US10793582B2 (en) 2015-10-22 2020-10-06 Mitsubishi Tanabe Pharma Corporation Bicyclic heterocyclic compound
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
EP3558979B1 (en) 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
US20220235013A1 (en) 2017-03-21 2022-07-28 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
FR3066761B1 (fr) 2017-05-23 2020-10-30 Centre Nat Rech Scient Nouveaux composes inhibiteurs des canaux ioniques
KR20200111163A (ko) 2017-12-21 2020-09-28 베링거 인겔하임 인터내셔날 게엠베하 Sos1 억제제로서의 신규 벤질아미노 치환 피리도피리미디논 및 유도체
IL277044B2 (en) 2018-03-05 2023-10-01 Bristol Myers Squibb Co Phenylpyrrolidinone formyl peptide 2 receptor agonists
CN109776607B (zh) 2019-02-21 2021-06-04 青岛海洋生物医药研究院 芳基磷氧类和芳基磷硫类化合物及其制备方法和应用
CA3130083A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
MX2021010319A (es) 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos biciclicos de heteroarilo y usos de estos.
CA3182745A1 (en) 2020-05-09 2021-11-18 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Sos1 inhibitor containing phosphorus

Also Published As

Publication number Publication date
EP4322962A1 (en) 2024-02-21
CA3216503A1 (en) 2022-10-20
ECSP23077322A (es) 2023-11-30
BR112023019030A2 (pt) 2023-10-24
AR125672A1 (es) 2023-08-02
WO2022219035A1 (en) 2022-10-20
JP2024513595A (ja) 2024-03-26
CL2023003045A1 (es) 2024-03-22
TW202304467A (zh) 2023-02-01
AU2022258751A1 (en) 2023-10-05
IL307448A (en) 2023-12-01
CN117500507A (zh) 2024-02-02
PE20240022A1 (es) 2024-01-04
DOP2023000218A (es) 2023-11-15
EP4074317A1 (en) 2022-10-19
KR20230170032A (ko) 2023-12-18
CO2023013469A2 (es) 2024-04-29

Similar Documents

Publication Publication Date Title
PH12019500932A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
CR20230485A (es) Derivados de fósforo como nuevos inhibidores de sos1
WO2018077944A3 (en) 4,5-annulated 1,2,4-triazolones
PH12018550173A1 (en) Pyrazolopyrimidine derivatives
WO2020126968A3 (en) Urea derivatives for use against proliferative diseases
WO2017198341A8 (en) MACROCYCLIC INDOLE DERIVATIVES
JOP20190193A1 (ar) ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
MY164730A (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PH12020500257A1 (en) Quinoline derivatives for treating infections with helminths
MX2017001637A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
PH12020500134A1 (en) Dihydrooxadiazinones
MX2022006466A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activacion inmune.
MY168413A (en) Amino-substituted imidazopyridazines
MX2019012803A (es) Nuevos derivados de pirazol biciclicos.
TN2017000258A1 (en) Pyrazolopyridinamines as mknk1 and mknk2 inhibitors
PH12020551891A1 (en) New quinoline derivatives
MX2022013388A (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activacion inmune.
JOP20220034A1 (ar) مركبات [1، 2، 4] تريازولو [1، 5-جـ] كوينازولين-5-أمين
PH12020550494A1 (en) Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors
PH12019500808A1 (en) Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof
MX2021011979A (es) Derivados del isocromeno como inhibidores de la fosfoinositida 3-cinasa.
TN2013000204A1 (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TN2014000091A1 (en) Amino-substituted imidazopyridazines